Acurx Pharmaceuticals Announces First Patient Enrolled in PATHFINDER Clinical Trial of Ibezapolstat in Multiply-Recurrent C. difficile Infection
Go back to Acurx Pharmaceuticals Announces First Patient Enrolled in PATHFINDER Clinical Trial of Ibezapolstat in Multiply-Recurrent C. difficile Infection| (NASDAQ: ACXP) | Delayed: 1.15 +0.01 (0.88%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $1.14 | 52 Week High | $ | |||
| Open | $1.18 | 52 Week Low | $ | |||
| Day High | $1.18 | P/E | N/A | |||
| Day Low | $1.13 | EPS | $ | |||
| Volume | 20,962 | |||||



